Drug-related problems in hospitalised Parkinson’s disease patients in China

Abstract

Background There has been a lack of studies on the types and severity of drug-related problems (DRPs) in hospitalised patients with Parkinson's disease (PD) in China until now. Objective To investigate the types and causes of DRPs, and to assess the severity of these DRPs in PD patients in neurology wards. Methods A retrospective study involving 209 PD inpatients was conducted at a tertiary hospital in China from January 2017 to December 2018. The identification and assessment of DRPs were based on the Pharmaceutical Care Network Europe (PCNE) tool version 8.03. The severity ratings of these DRPs was assessed based on the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) classification.Results A total of 274 DRPs with an average of 1.31±1.00 problems per patient were identified, in which 83.3% of the population had at least one DRP. Using the PCNE classification system, the most common domain of DRPs was "Other, P3" (62.8%), followed by "Treatment effectiveness, P1" (19.3%) and "Treatment safety, P2" (17.9%). A total of 88.7% of the DRPs were rated at severity categories B to D (causing no or potential harm), whereas 11.3% were rated as categories E to H (causing actual harm). Conclusions These data indicate that the prevalence of DRPs is high among PD patients. The identification of different subtypes of DRPs may facilitate risk reduction for PD patients.

Characterization of Medication Errors in a Medical Intensive Care Unit of a University Teaching Hospital in South Korea

“…In addition, the NCC-MERP classification tool used to measure the ME-related outcome severity in this present study has been criticized because of potential subjectivity as well as a mixture of a severity assessment scale and a tool for recording ME occurrences 50 . However, considering the high interrater reliability and criterion validity as suggested in a previous study, use of the NCC-MERP taxonomy system with modifications in this study and in many other previous studies 20–22 was considered acceptable 51 . Furthermore, several high-risk medications, including IV electrolytes such as potassium, calcium, and magnesium, frequently used in the MICU were not assessed for appropriateness in this present study because the exact amount administered to each patient was not recorded in the EMR system.…”

“…The identified ME incidents were verified by 2 independent reviewers including 1 academic faculty pharmacist and 1 physician specialized in critical care. Severity of patient outcome owing to the ME was classified based on the modified National Coordinating Council for Medication Error Reporting and Prevention (NCC-MERP) taxonomy (Table 2), 19 which is one of the most commonly used ME-related outcome severity classification systems 20–22 . Any discrepancies in the recorded ME incidents and the associated outcome severity were resolved by interprofessional research team discussion led by an academic faculty pharmacist and a medical intensivist.…”

“…1 2), 19 which is one of the most commonly used ME-related outcome severity classification systems. [20][21][22] Any discrepancies in the recorded ME incidents and the associated outcome severity were resolved by interprofessional research team discussion led by an academic faculty pharmacist and a medical intensivist.…”

Identification of drugs-related problems and pharmacists’ interventions in a hospital in Southern Brazil

“…Com relação as causas dos PRMs, o domínio mais frequentemente encontrado no estudo foi o de seleção de dose com 46,7% e o de seleção do medicamento com 32,5%. Esses dados sáo similares dos encontrados em estudos internacionais, nos quais a principal causa dos PRMs está ligada a seleção do medicamento em primeiro lugar e em segundo lugar ao domínio de seleção de dose 14,20,21,22,23,24 .…”

Global research trends and hotspots in pharmaceutical care: a bibliometric analysis and visualisation using CiteSpace and VOSviewer

“…The distribution of pharmacists’ clinical departments and the absence of the role of clinicians lead to relatively few pharmacists participating in drug education activities 3. In daily diagnosis and treatment, it is difficult for most inpatients and outpatients to get pharmaceutical service from professional pharmacists, which results in patients repeating or seriously abusing drugs, and even mutual antagonism of drug efficacy and many adverse events 4–6…”